Adrenal and Paraganglionic Tumors

PPGLomics: An Interactive Platform for Pheochromocytoma and Paraganglioma Transcriptomics

PPGLomics provides a web-based platform for analyzing PPGL transcriptomics data, integrating two datasets and offering tools for differential expression, correlation, survival analysis, and visualization.

TEAD1 signaling modulates adrenal chromaffin maturation

The paper identifies TEAD1 signaling as a critical regulator of chromaffin cell differentiation and function, and shows that SB699551 modulates this signaling to suppress pheochromocytoma cell proliferation.

TR-107, a novel mitochondrial ClpP agonist, induces robust antitumor activity against preclinical models of adrenocortical carcinoma

This study evaluates TR-107, a mitochondrial ClpP agonist, showing antitumor effects in ACC cell lines and organoids, with synergistic activity when combined with IGF-1R inhibitors.

Updating ACC preclinical models: characterization of two new patient-derived cell lines

This paper describes the development and characterization of two new patient-derived ACC cell lines, SMAC-2 and SMAC-3, highlighting their molecular and functional features for preclinical research.

Unbiased CRISPR Synthetic Lethal Screening for Genetic Vulnerabilities in Succinate Dehydrogenase (SDH)-loss Model of Paraganglioma

The paper uses CRISPR screening to identify genetic vulnerabilities in SDH-deficient paraganglioma cells, finding the neddylation pathway as a potential therapeutic target.

Phaeochromocytomas and paragangliomas harbour tumour-initiating SOX2+ stem cells

This study identifies SOX2+ cells in phaeochromocytomas and paragangliomas as potential tumour-initiating stem cells capable of expansion and metastasis.

Establishment of a patient-derived adrenocortical carcinoma 3D tumor construct platform for evaluation of therapeutic strategies

This paper develops patient-derived ACC tumor constructs to evaluate therapeutic strategies, showing they can test chemotherapies, targeted therapies, and immunotherapies.

Patient-derived organoids reveal hypoxia-driven plasticity and therapeutic vulnerabilities in pheochromocytomas and paragangliomas

This study uses patient-derived organoids to model pheochromocytomas and paragangliomas, revealing hypoxia-driven plasticity and therapeutic vulnerabilities, including responses to abemaciclib.

Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma

This paper identifies DLK1 as a novel immunotherapeutic target in adrenocortical carcinoma, showing it regulates tumor cell plasticity and chemoresistance, and demonstrates the efficacy of a DLK1-targeting antibody-drug conjugate.

Bimodal genomic approach predicting Semaphorin 7A (SEMA7A) as prognostic biomarker in adrenocortical carcinoma

This paper identifies SEMA7A as a prognostic biomarker in adrenocortical carcinoma using transcriptome data from TCGA and NCI samples, showing its association with poor prognosis and specific signaling pathways.

Transcriptional Subtypes on Immune Microenvironment and Predicting Postoperative Recurrence and Metastasis in Pheochromocytoma and Paraganglioma

The paper identifies three transcriptional subtypes of PPGLs based on immune and genomic features, linking them to prognosis and potential therapeutic targets.

Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinoma

This paper identifies DLK1 as a marker of adrenocortical stem/progenitor cells that predicts malignancy in adrenocortical carcinoma and is detectable in patient serum.

A genetic signature predicts aggressive paraganglioma sensitivity to dual PI3K-CDK4/6 inhibition therapy

Single Nuclei Sequencing Reveals Replication Stress in Adrenocortical Carcinoma

The paper uses single nuclei RNA sequencing to identify replication stress and DNA damage response in adrenocortical carcinoma, suggesting ATR as a potential therapeutic target.

An integrated bioinformatics approach to identify candidate biomarkers and the evaluation of drugs for pheochromocytoma

This study identifies potential biomarkers and evaluates Lenvatinib as a drug target for pheochromocytoma using bioinformatics analysis of gene expression and molecular docking.

Functional characterization of germline variants in the TMEM127 tumor suppressor reveals novel insights into its membrane topology and trafficking

The paper functionally characterizes germline TMEM127 variants, identifying pathogenic mutations and revealing a fourth transmembrane domain and an endocytic motif.